An Inflection Point for Long-Acting Injectables: How PURASORB® and Technological Advances are Expanding the Role of LAIs in Pharmaceutical Growth Strategies

Session details:

Long-acting injectables (LAIs) have a strategic importance across the pharmaceutical industry. In addition to improving treatment convenience and adherence, LAIs can enable differentiated product profiles, support lifecycle management, and create new opportunities for both innovative and reformulated APIs. However, successful development remains technically demanding. Formulators must first identify feasible formulation pathways based on the API and desired product profile, then simultaneously balance interconnected requirements, including pharmacokinetics, injectability, stability, manufacturability, and scalability.

Corbion is a leading supplier of GMP-grade biodegradable polymers for controlled-release drug delivery. Its PURASORB® portfolio includes well-established lactide- and glycolide-based polymers as well as innovative polymers designed to expand the formulation possibilities for injectable depot systems.

This presentation will examine how market dynamics and technological advances are increasing the relevance of long-acting injectable technologies. It will discuss the role of polymer selection and material properties in meeting the requirements of established delivery approaches, while also considering emerging opportunities in areas such as scalable microsphere manufacturing and the potential of AI to accelerate development and address unmet formulation challenges.